Branched end reactants and polymeric hydrogel tissue adhesives therefrom
AssigneeActamax Surgical Materials, LLC
InventorsSamuel David Arthur, Garret D. Figuly
Life of this patent
Estimating the term…
Loading patent…
AssigneeActamax Surgical Materials, LLC
InventorsSamuel David Arthur, Garret D. Figuly
Estimating the term…
Branched end reactants having two or three functional groups at the ends are disclosed. The branched end reactants are used to prepare crosslinked hydrogel tissue adhesives, which have a good balance of mechanical properties in an aqueous environment. Kits comprising the branched end reactants and methods for applying a coating to an anatomical site on tissue of a living organism are also disclosed.
A composition of matter comprising at least one compound of the formula:
A kit comprising:
A hydrogel made by a process comprising reacting:
A method for applying a coating to an anatomical site on tissue of a living organism comprising:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Polymers modified by chemical after-treatment: with organic compounds
Containing amino group: acyclic
Adhesives based on polyethers obtained by reactions forming an ether link in the main chain ; Adhesives based on derivatives of such polymers:…
Characterised by the polymer type: containing nitrogen, e.g. polyetheramines or Jeffamines
About 3 years 4 months of term left · ends 20 Feb 2030 (estimated)
The invention relates to the field of medical adhesives. More specifically, the invention relates to branched end reactants that can used to prepare hydrogel tissue adhesives with improved mechanical properties. The invention also relates to kits and methods for applying a coating to an anatomical site on tissue of a living organism using a polymer tissue adhesive formed using at least one branched end reactant.
Tissue adhesives have many potential medical applications, including wound closure, supplementing or replacing sutures or staples in internal surgical procedures, adhesion of synthetic onlays or inlays to the cornea, drug delivery devices, and as anti-adhesion barriers to prevent post-surgical adhesions. Conventional tissue adhesives are generally not suitable for a wide range of adhesive applications. For example, cyanoacrylate-based adhesives have been used for topical wound closure, but the release of toxic degradation products limits their use for internal applications. Fibrin-based adhesives are slow curing, have poor mechanical strength, and pose a risk of viral infection. Additionally, the Fibrin-based adhesives do not covalently bind to the underlying tissue.
Several types of hydrogel tissue adhesives have been developed, which have improved adhesive and cohesive properties and are nontoxic. These hydrogels are generally formed by reacting a component having nucleophilic groups with a component having electrophilic groups, which are capable of reacting with the nucleophilic groups of the first component, to form a crosslinked network via covalent bonding. However, these hydrogels typically swell or dissolve away too quickly, or lack sufficient adhesion or mechanical strength, thereby decreasing their effectiveness as surgical adhesives.
In various embodiments, the invention provides branched end reactants that are useful as crosslinking agents for preparing hydrogels having a good balance of mechanical properties (i.e., elongation to break, tensile strength, and water swell) in an aqueous environment. The branched end reactants can be linear or branched polymers having two or three functional groups at each of the ends of the polymer chain or at the end of the polymer arms. The multiplicity of functional groups increases the statistical probability of reaction at a given chain end and allows more efficient incorporation of the linear or branched molecules into a polymer network. As a result, hydrogels formed using the branched end reactants disclosed herein have a reduced degree of swelling and a slower rate of hydrolytic degradation compared to hydrogels prepared with similar crosslinking molecules having only a single functional group at each end. Therefore, linear or branched crosslinking molecules which promote better elongation can be employed in the hydrogel without also incurring high water swelling and fast degradation. Additionally, branched end reactants having a limited number of two or three functional groups at the ends of the polymer chain or at the end of the polymer arms provide better control of crosslinking than multi-functional site containing polymers, which are known in the art, that have polymeric end blocks with a large multiplicity of functional groups.
The hydrogels formed using the branched end reactants disclosed herein may be useful as an adhesive for medical and veterinary applications including, but not limited to, wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, ophthalmic procedures, and as a plug to seal a fistula or the punctum. Additionally, the hydrogels may have utility in drug delivery, and in anti-adhesive applications.
The following definitions are used herein and should be referred to for interpretation of the claims and the specification.